Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability

Ravindra S. Dhumal

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Shailesh V. Biradar,

Shailesh V. Biradar

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Suyog Aher,

Suyog Aher

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Professor Anant R. Paradkar,

Corresponding Author

Professor Anant R. Paradkar

Institute of Pharmaceutical Innovations, University of Bradford, Bradford, UK

¹Institute of Pharmaceutical Innovations, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK. E-mail: [email protected]Search for more papers by this author

Ravindra S. Dhumal,

Ravindra S. Dhumal

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Shailesh V. Biradar,

Shailesh V. Biradar

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Suyog Aher,

Suyog Aher

Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy and Research Centre, Erandawane, Pune, India

Search for more papers by this author

Professor Anant R. Paradkar,

Corresponding Author

Professor Anant R. Paradkar

Institute of Pharmaceutical Innovations, University of Bradford, Bradford, UK

¹Institute of Pharmaceutical Innovations, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK. E-mail: [email protected]Search for more papers by this author

First published: 08 January 2010

https://doi.org/10.1211/jpp.61.06.0006

Citations: 19

Share a link

Email
Wechat
Bluesky

Abstract

Objectives Cefuroxime axetil (CA), a poorly soluble, broad spectrum cephalosporin ester prodrug, is hydrolysed by intestinal esterase prior to absorption, leading to poor and variable bioavailability. The objective was therefore to formulate a stable amorphous solid dispersion of the drug with enhanced solubility and stability against enzymatic degradation.

Methods Spray drying was used to obtain a solid dispersion of CA with Gelucire 50/13 and Aerosil 200 (SDCAGA), and a solid dispersion of CA with polyvinyl pyrrolidone (SDCAP); amorphous CA (ACA) was obtained by spray drying CA alone. The formulations were characterized by differential scanning calorimetry, X-ray powder diffraction, scanning electron microscopy and Fourier transform infrared spectroscopy studies, and compared for solubility, dissolution and bioavailability in rats.

Key findings SDCAP and SDCAGA showed improved solubility and dissolution profiles owing to amorphization and formation of solid dispersions with hydrophilic carriers. The improved stability of amorphous CA in solid dispersions compared to ACA alone was attributed to hydrogen bonding interactions involving the amide of CA with the carbonyl of polyvinyl pyrrolidone in SDCAP, whereas in SDCAGA the interactions were at multiple sites involving the amide and carbonyl of CA with the carbonyl and hydroxyl of Gelucire 50/13. However, SDCAGA showed superior bioavailability compared to SDCAP, ACA and CA.

Conclusions Improvement in physical stability of solid dispersions was attributed to hydrogen bonding, while improvement in bioavailability of SDCAGA compared to SDCAP, in spite of comparable solubility and dissolution profile, may be attributed to Gelucire, which utilizes intestinal esterase for lipolysis, protecting the prodrug from enzymatic degradation to its non-absorbable base form.

References

1 McEvoy GK. Cephalosporins: Cefuroxime sodium. Cefuroxime axetil. In: AHFS Drug Information. Bethesda, MD: American Society for Hospital Pharmacists, 2003: 223–231.
Google Scholar
2 Finn A. et al. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dipos 1987; 8: 519–526.
10.1002/bdd.2510080604
CAS PubMed Web of Science® Google Scholar
3 Crisp HA, Clayton JC. Amorphous form of cefuroxime ester. US Patent 4,562,181, 1985.
Google Scholar
4 Crisp HA et al. Preparation of a highly pure substantially amorphous form of cefuroxime axetil. US Patent 4,820,1833, 1989.
Google Scholar
5 Dhumal RS et al. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm 2008; 70: 109–115.
10.1016/j.ejpb.2008.04.001
CAS PubMed Web of Science® Google Scholar
6 Weuts I. et al. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm 2005; 59: 119–126.
10.1016/j.ejpb.2004.05.011
CAS PubMed Web of Science® Google Scholar
7 Ambike AA et al. Stability study of amorphous valdecoxib. Int J Pharm 2004; 282: 151–162.
10.1016/j.ijpharm.2004.06.009
CAS PubMed Web of Science® Google Scholar
8 Yokoi Y. et al. Changes in surface properties by granulation and physicochemical stability of granulated amorphous cefditoren pivoxil with additives. Int J Pharm 2004; 280: 67–75.
10.1016/j.ijpharm.2004.05.005
CAS PubMed Web of Science® Google Scholar
9 Jun SW et al. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. J Pharm Pharmacol 2005; 57: 1529–1537.
10.1211/jpp.57.12.0003
CAS PubMed Web of Science® Google Scholar
10 Pillay V., Fassihi R. A new method for dissolution studies of lipid-filled capsules employing nifedipine as a model drug. Pharm Res 1999; 16(2): 333–337.
10.1023/A:1011959914706
CAS PubMed Web of Science® Google Scholar
11 Chauhan B. et al. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide. Eur J Pharm Sci 2005; 26: 219–230.
10.1016/j.ejps.2005.06.005
CAS PubMed Web of Science® Google Scholar
12 Shimpi SL et al. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm Res 2005; 22(10): 1727–1734.
10.1007/s11095-005-6694-1
CAS PubMed Web of Science® Google Scholar
13 Jiménez-Torres NV. Bases bioquímicas de la nutrición artificial: macronutrientes. In: NV Jiménez, ed. Mezclas Intravenosas y Nutrición Artificial, 3rd edn. Valencia: Nau Llibres, 1988: 283–305 [in Spanish].
Google Scholar
14 Crauste-Manciet S. et al. Cefpodoxime-proxetil protection from intestinal lumen hydrolysis by oil-in-water submicron emulsions. Int J Pharm 1998; 165: 97–106.
10.1016/S0378-5173(98)00008-8
CAS Web of Science® Google Scholar
15 Prabhu S. et al. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int J Pharm 2005; 301: 209–216.
10.1016/j.ijpharm.2005.05.032
CAS PubMed Web of Science® Google Scholar
16 Passerini N. et al. Characterization of carmazepine-gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci 2002; 91: 699–707.
10.1002/jps.10085
CAS PubMed Web of Science® Google Scholar
17 Zhao YH et al. Evaluation of intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 2003; 38: 233–243.
10.1016/S0223-5234(03)00015-1
CAS PubMed Web of Science® Google Scholar
18 Ruiz-Balaguer N. et al. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. Int J Pharm 2002; 34: 101–111.
10.1016/S0378-5173(01)00956-5
Web of Science® Google Scholar
19 Sekikawa H. et al. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem Pharm Bull 1978; 26: 118–126.
10.1248/cpb.26.118
CAS Web of Science® Google Scholar
20 Yoshioka M. et al. Inhibition of indomethacin crystallization in polyvinylpyrrolidone coprecipitates. J Pharm Sci 1995; 84: 983–986.
10.1002/jps.2600840814
CAS PubMed Web of Science® Google Scholar
21 Van den Mooter G. et al. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 1998; 164: 67–80.
10.1016/S0378-5173(97)00401-8
Web of Science® Google Scholar
22 Van den Mooter G. et al. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001; 12: 261–269.
10.1016/S0928-0987(00)00173-1
PubMed Web of Science® Google Scholar
23 Matsumoto T., Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indo-methacin crystallization. Pharm Res 1999; 16: 1722–1728.
10.1023/A:1018906132279
CAS PubMed Web of Science® Google Scholar
24 Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997; 14: 1691–1698.
10.1023/A:1012167410376
CAS PubMed Web of Science® Google Scholar
25 Raghavan SR et al. Rheology of silica dispersions in organic liquids: new evidence for solvation forces dictated by hydrogen bonding. Langmuir 2000; 16: 7920–7930.
10.1021/la991548q
CAS Web of Science® Google Scholar
26 Vippagunta SR et al. Solid-state characterization of nifedipine solid dispersions. Int J Pharm 2002; 236: 111–123.
10.1016/S0378-5173(02)00019-4
CAS PubMed Web of Science® Google Scholar
27 Leuner G., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47–60.
10.1016/S0939-6411(00)00076-X
CAS PubMed Web of Science® Google Scholar
28 Broman E. et al. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water-soluble drug. Int J Pharm 2001; 222: 139–151.
10.1016/S0378-5173(01)00709-8
CAS PubMed Web of Science® Google Scholar
29 Dordunoo SK et al. Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm 1991; 17: 1685–1713.
10.3109/03639049109057315
CAS Web of Science® Google Scholar
30 Chambin O., Jannin V. Interest of multifunctional lipid excipients: Case of Gelucire 44/14. Drug Dev Ind Pharm 2005; 31: 527–532.
10.1080/03639040500215750
CAS PubMed Web of Science® Google Scholar
31 Nair R. et al. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int J Pharm 2002; 240: 11–22.
10.1016/S0378-5173(02)00083-2
CAS PubMed Web of Science® Google Scholar
32 Schmitt E. et al. Moisture dependent crystallization of amorphous lamotrigine mesylate. J Pharm Sci 1996; 85: 1215–1219.
10.1021/js9600484
CAS PubMed Web of Science® Google Scholar
33 Shalaev EY, Zografi G. How does residual water affect the solid-state degradation of drugs in the amorphous state J Pharm Sci 1996; 85: 1137–1141.
10.1021/js960257o
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume61, Issue6

June 2009

Pages 743-751

Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability

Abstract

References

Citing Literature

References

Related

Information